{"gene":"P2RY1","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2015,"finding":"Crystal structures of human P2Y1R revealed two distinct ligand-binding sites: nucleotide antagonist MRS2500 binds within the seven transmembrane bundle (orthosteric site, distinct in shape and location from P2Y12R), while non-nucleotide antagonist BPTU binds an allosteric pocket on the external receptor–lipid bilayer interface entirely outside the helical bundle.","method":"X-ray crystallography at 2.7 Å (MRS2500 complex) and 2.2 Å (BPTU complex)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structures with two independent ligand complexes, replicated by subsequent MD simulations confirming functional relevance","pmids":["25822790"],"is_preprint":false},{"year":2016,"finding":"All-atom MD simulations (20 µs total) showed that ADP activates P2Y1R by breaking an ionic lock within the receptor and forming a continuous water channel, while BPTU acts as an antagonist by stabilizing extracellular helix bundles and increasing lipid order, and MRS2500 blocks signaling by occupying the orthosteric binding site.","method":"Long-timescale all-atom molecular dynamics simulations (20 µs)","journal":"Angewandte Chemie International Edition","confidence":"Medium","confidence_rationale":"Tier 1 method (extensive MD) / Moderate — single computational study with mechanistic detail but no experimental mutagenesis validation reported in abstract","pmids":["27460867"],"is_preprint":false},{"year":1997,"finding":"Human P2Y1 receptor expressed in Jurkat cells functions as an ADP receptor coupled to intracellular calcium mobilization; 2-methylthio-ADP is the most potent agonist, ADP is a full agonist, and ATP acts as a competitive antagonist. The receptor is expressed in platelets and megakaryoblastic cells, identifying it as the platelet P2T purinoceptor.","method":"Heterologous expression in Jurkat cells with HPLC-purified nucleotide agonist/antagonist pharmacology; RT-PCR in platelets and megakaryoblastic cell lines","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological characterization replicated across multiple labs and cell systems","pmids":["9038354"],"is_preprint":false},{"year":1998,"finding":"P2Y1 receptor is an ADP-specific Gq-coupled receptor; when ATP contamination is removed by creatine phosphate/creatine phosphokinase treatment, purified 2-MeSATP and 2-ClATP act as competitive antagonists (not agonists) at both rat and human P2Y1 receptors, demonstrating ATP is a competitive antagonist.","method":"Pharmacological assays with creatine phosphate/creatine phosphokinase nucleotide purity control in endothelial cells and P2Y1-transfected Jurkat cells","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous purity controls, replicated in two cell systems (endothelial and Jurkat), findings consistent with multiple other labs","pmids":["9547364"],"is_preprint":false},{"year":1998,"finding":"Selective P2Y1 competitive antagonists A2P5P and A3P5P inhibit ADP-induced platelet shape change, aggregation, and calcium mobilization but do not affect ADP-induced inhibition of adenylyl cyclase in platelets, demonstrating P2Y1 is necessary for ADP-induced platelet aggregation and calcium mobilization but a separate ADP receptor couples to adenylyl cyclase.","method":"Pharmacological antagonism with selective P2Y1 antagonists in human platelets and P2Y1-expressing Jurkat cells; fura-2 calcium measurements","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — selective antagonists in native platelet system plus heterologous expression system, results replicated across labs","pmids":["9639511"],"is_preprint":false},{"year":1998,"finding":"Site-directed mutagenesis of the human P2Y1 receptor identified key residues for antagonist binding: F226A, K280A, and Q307A mutations in transmembrane helices 5, 6, and 7 abolished antagonist MRS2179 potency; H132, T222, and Y136 had modulatory roles. A rhodopsin-based molecular model localized the nucleotide binding site to TM regions 3, 6, and 7.","method":"Site-directed mutagenesis of transmembrane domain residues combined with functional assay (phospholipase C stimulation) and computational molecular modeling","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with functional readout identifying specific binding residues in single lab, multiple mutations tested","pmids":["9554879"],"is_preprint":false},{"year":2004,"finding":"Purified human P2Y1 receptor reconstituted in proteoliposomes with heterotrimeric Gq(alpha)beta1gamma2 directly stimulates GTP hydrolysis upon agonist addition (up to 50-fold with 2MeSADP plus RGS4). Agonist affinity order under conditions preventing nucleotide metabolism: 2MeSADP > ADP = 2MeSATP = ATPalphaS = ADPbetaS >> ATP. ATP is a partial agonist with 20-fold lower potency than ADP.","method":"Receptor purification from baculovirus/Sf9 system; reconstitution in proteoliposomes with purified heterotrimeric G proteins; radioligand binding ([3H]MRS2279); steady-state GTP hydrolysis","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution with purified proteins, multiple orthogonal methods (binding, GTPase, agonist rank order under controlled conditions)","pmids":["14742685"],"is_preprint":false},{"year":2005,"finding":"P2Y1 receptor desensitization in platelets and 1321N1 cells is mediated by protein kinase C, not by GRK2 or GRK6. In contrast, P2Y12 desensitization requires GRKs. Dominant-negative GRK mutants and GRK siRNA did not affect P2Y1 desensitization, while PKC inhibition abolished it.","method":"Dominant-negative GRK mutant overexpression; GRK-specific siRNA knockdown; PKC inhibition; platelet aggregation and calcium mobilization assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (dominant-negative, siRNA, pharmacological inhibition) in two cell systems","pmids":["15665114"],"is_preprint":false},{"year":2008,"finding":"P2Y11 receptor forms hetero-oligomers with P2Y1 receptor when co-expressed in HEK293 cells, detected by co-pulldown, co-immunoprecipitation, and FRET. This interaction promotes agonist-induced internalization of P2Y11 (which cannot undergo endocytosis alone), and alters the ligand selectivity of P2Y11. Endogenous P2Y1 in HEK293 cells supports GFP-P2Y11 endocytosis, abolished by P2Y1 siRNA.","method":"Co-pulldown, co-immunoprecipitation, FRET; siRNA knockdown; fluorescence microscopy of receptor internalization in 1321N1 and HEK293 cells","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, FRET, and siRNA rescue with functional consequence (internalization), multiple orthogonal methods","pmids":["17824841"],"is_preprint":false},{"year":2016,"finding":"After agonist activation, P2Y1 is sorted to lysosomes for degradation via a ubiquitin-independent pathway requiring a YPX3L motif in the second intracellular loop that binds the adaptor protein ALIX. Depletion of ALIX or mutation of the YPX3L motif blocks P2Y1 sorting into multivesicular endosome lumens and prevents lysosomal degradation.","method":"ALIX siRNA depletion; site-directed mutagenesis of YPX3L motif; fluorescence microscopy tracking lysosomal sorting; degradation assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mutagenesis of binding motif combined with siRNA knockdown and functional degradation assay in single lab","pmids":["27301021"],"is_preprint":false},{"year":2010,"finding":"P2Y1 receptor recycling occurs via a slow retromer-independent pathway regulated by sorting nexin 1 (SNX1). SNX1 inhibition dramatically increased the rate of P2Y1 receptor recycling, while inhibition of retromer components Vps26 and Vps35 had no effect. P2Y12 receptor returns to the cell surface via a rapid SNX1-independent route.","method":"SNX1 dominant-negative/knockdown; Vps26/Vps35 inhibition; fluorescence microscopy of receptor recycling kinetics","journal":"Traffic (Copenhagen, Denmark)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown and negative controls distinguishing receptor-specific trafficking, single lab","pmids":["20070609"],"is_preprint":false},{"year":2008,"finding":"P2Y1 receptor constitutively dimerizes (44% of receptors as dimers at rest), with agonist exposure increasing dimerization to 85–100%; receptor dimers are required for internalization but not for activation. Removal of the C-terminal 19 amino acids abolished both dimerization and internalization; the last four amino acids (DTSL) mediate constitutive dimerization through binding to the scaffolding protein NHERF-2.","method":"FRET donor photobleaching in living HEK293 cells; C-terminal deletion mutants; functional assays for activation vs. internalization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — quantitative FRET in living cells with defined deletion mutants linking dimerization to specific C-terminal sequences and scaffolding protein, multiple mutants tested","pmids":["18270199"],"is_preprint":false},{"year":2004,"finding":"Membrane depolarization potentiates IP3-dependent Ca2+ mobilization by P2Y1 receptor in megakaryocytes via a voltage sensitivity intrinsic to the receptor itself (not voltage-gated Ca2+ channels, G-protein betagamma subunits, or downstream signals). Megakaryocytes from P2Y1-/- mice lacked voltage-dependent Ca2+ release during ADP stimulation.","method":"Whole-cell patch clamp combined with fura-2 fluorescence in megakaryocytes; nifedipine controls; P2Y1 knockout mice; dialysis with GTPgammaS and AlF4-","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout combined with electrophysiology and pharmacological dissection in native cells, multiple controls ruling out alternative mechanisms","pmids":["15528188"],"is_preprint":false},{"year":2001,"finding":"P2Y1 receptor activation by 2-MeSADP stimulates ERK1/2 (EC50 ~5 nM) and selected SAPK/JNK isoforms but not p38 MAPK. Transient ERK activation involves cooperative effects of PI3K, Src, and PKC via Ras, while sustained ERK activation is Ras-independent and PI3K-dependent, culminating in Elk-1 phosphorylation. Transient SAPK activity via MKK4 is required for P2Y1-mediated apoptosis (caspase-3 activation). These responses are pertussis toxin-insensitive, indicating Gq-coupling.","method":"Selective kinase inhibitors; dominant-negative Ras and MKK4 mutants; pertussis toxin; phospho-specific Western blots; caspase-3 and cell number assays in stably expressing cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple dominant-negative constructs and pharmacological inhibitors in single lab with multiple orthogonal signaling readouts","pmids":["11278310"],"is_preprint":false},{"year":2003,"finding":"P2Y1 receptor activation by ATP in chick and mouse myotubes stimulates transcription of acetylcholinesterase and acetylcholine receptor subunit genes via a pathway involving PKC, intracellular Ca2+ release, ERK phosphorylation, and culminating in Elk-1 transcription factor activation. Two Elk-1 binding sites in the AChE promoter are sufficient to drive ATP-induced reporter gene transcription.","method":"Promoter-reporter constructs; dominant-negative and constitutively active kinase mutants; kinase inhibitors; gel mobility shift assays; nuclear phospho-Elk-1 immunostaining; P2Y1-selective antagonist blockade","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (reporter assays, dominant-negative constructs, EMSA, antagonist) in single lab","pmids":["12805285"],"is_preprint":false},{"year":2006,"finding":"Selective activation of P2Y1 receptors in astrocytes triggers glutamate release by regulated exocytosis. The mechanism requires Ca2+ release from internal stores and is controlled by TNFalpha and PGE2: P2Y1R activation induces release of both TNFalpha and PGE2, and blocking either one significantly reduces glutamate release. Astrocytes from TNFalpha-/- or TNFR1-/- mice show deficient P2Y1R-dependent Ca2+ signaling and glutamate release.","method":"TIRF imaging of fluorescent glutamatergic vesicles; calcium imaging; TNFalpha/TNFR1 knockout mice; cyclooxygenase inhibitors; P2Y1-selective pharmacology; acute hippocampal slices","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct vesicle imaging, genetic knockout confirmation, pharmacological dissection, in vivo slice validation","pmids":["16882655"],"is_preprint":false},{"year":2012,"finding":"P2Y1 receptor (P2ry1) mediates the fast inhibitory junctional potential (fIJP) in murine colon via purinergic neurotransmission. P2ry1-/- mice completely lacked fIJPs and purinergic contractile responses. β-NAD and its metabolite ADPR caused P2Y1R-mediated hyperpolarization in wild-type but not P2ry1-/- mice. Colonic transit was significantly delayed in P2ry1-/- mice.","method":"P2ry1 knockout mice; electrophysiology (intracellular recordings); contractile experiments; picospritz neurotransmitter candidates; video imaging of colonic transit","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal functional readouts and pharmacological confirmation","pmids":["22371476"],"is_preprint":false},{"year":2014,"finding":"Uridine adenosine tetraphosphate (Up4A) acts as a potent native agonist for P2Y1R in human and mouse colon muscles, causing relaxation and hyperpolarization via P2Y1R-SK channel activation. Up4A responses were blocked by MRS2500 and abolished in P2ry1-/- mice. Up4A induced MRS2500-sensitive Ca2+ transients in 1321N1 cells expressing human P2Y1R.","method":"P2ry1 knockout mice; isometric tension measurements; intracellular electrophysiology; isolated PDGFRα+ cells; heterologous expression calcium assays; HPLC metabolite analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout, multiple tissue preparations, heterologous expression, metabolite controls","pmids":["25341729"],"is_preprint":false},{"year":2003,"finding":"P2Y1 receptor is involved in ADP-stimulated microglial cell migration, in addition to P2Y12. Pharmacological inhibition and siRNA knockdown of P2Y1 reduced ADP-stimulated microglial migration. TGF-β treatment increased P2Y1 and P2Y12 expression and ADP-induced migration, while LPS abrogated both receptor expression and migration.","method":"P2Y1/P2Y12 selective pharmacological inhibitors; P2Y1 siRNA knockdown; microglial migration assay; calcium mobilization assays; qPCR for receptor expression","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological inhibition in primary microglia culture, single lab","pmids":["20681951"],"is_preprint":false},{"year":2005,"finding":"P2Y1 receptor mediates ADP-induced Rac GTPase activation via Gq-dependent pathway in platelets, independently of P2Y12 and GPIIb/IIIa and PI3K. P2Y12 receptor alone cannot activate Rac per se, but secreted ADP potentiates Rac activation from other agonists via P2Y12. Rac activation by P2Y1 drives PAK activation and actin polymerization.","method":"Rac-GTP pulldown assay; selective P2Y1 and P2Y12 antagonists; P2Y1 knockout mice platelets; GPIIb/IIIa and PI3K inhibitors; PAK kinase assay; actin polymerization","journal":"Journal of thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mice plus selective pharmacology plus biochemical effector assays","pmids":["16194206"],"is_preprint":false},{"year":2001,"finding":"P2Y1 receptor mediates ADP-induced platelet shape changes including centralization of secretory granules, formation of filopodia, actin polymerization, and cytoskeletal translocation of cdc42, rac1, and rhoA in an integrin αIIbβ3-dependent manner. P2YT (P2Y12) receptor is required for stable macroaggregate formation and amplification of actin polymerization but not early platelet activation steps.","method":"Selective antagonists A2P5P (P2Y1) and AR-C67085 (P2Y12); electron microscopy; actin polymerization assay; subcellular fractionation for small GTPases","journal":"Thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective pharmacological dissection in native platelets with multiple morphological and biochemical readouts, single lab","pmids":["11341507"],"is_preprint":false},{"year":2003,"finding":"P2Y1 receptor-mediated Ca2+ signaling in astrocytes exhibits frequency-dependent negative feedback via protein kinase C, with high-frequency stimulation producing rapid Ca2+ oscillations. The PKC-dependent oscillation mechanism was mapped to Thr339 in the C-terminus of P2Y1R; mutation of this residue eliminated PKC-mediated negative feedback.","method":"Calcium imaging; PKC inhibitors; site-directed mutagenesis of P2Y1R C-terminal Thr339; frequency-dependent stimulation protocols in primary astrocytes","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis mapping to specific residue combined with calcium imaging, single lab","pmids":["12805284"],"is_preprint":false},{"year":2014,"finding":"P2Y1 receptor in rat cortical astrocytes inhibits GABA transport (GAT-1 and GAT-3) by reducing transporter Vmax. This inhibition requires PLC activation and intracellular calcium release from stores, as it was blocked by PLC inhibitor U73122, BAPTA-AM (intracellular calcium chelation), and depletion of calcium stores with cyclopiazonic acid.","method":"P2Y1-selective agonist (2-MeSADP) and antagonist (MRS2179); GABA transport kinetics (Vmax/Km); PLC inhibitor; BAPTA-AM; calcium store depletion; primary astrocyte cultures","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective pharmacology with multiple mechanistic controls (PLC, Ca2+ chelation, store depletion) in single lab","pmids":["24733747"],"is_preprint":false},{"year":2015,"finding":"P2Y1 receptor activation in satellite glial cells (SGCs) couples to and activates TRPV4 ion channel through PKC. P2Y1-selective agonist (2-MeSADP) increased [Ca2+]i in SGCs expressing TRPV4, and responses were enhanced in TRPV4-expressing HEK293 cells; PKC inhibitors prevented P2Y1 receptor activation of TRPV4.","method":"Calcium imaging in isolated DRG neurons with attached SGCs; TRPV4 knockout mice; P2Y1-selective agonist/antagonist; PKC inhibitors; HEK293 co-expression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout, co-expression system, and pharmacological inhibition, single lab","pmids":["26475857"],"is_preprint":false},{"year":2004,"finding":"NTPDase1 co-localizes with P2Y1 receptor in caveolae of human placental endothelial cells, and enzymatic activity of NTPDase1 controls the local concentration of ADP/ATP available to activate P2Y1R. In NTPDase1-/- mice, P2Y1 receptor-dependent endothelial relaxation is dramatically enhanced (EC50 for ADP shifted from 14 µM to 0.35 µM) and P2Y1 receptors become more extensively desensitized.","method":"Immunohistochemistry and immuno-electron microscopy of human placenta; NTPDase1 knockout mice; vascular ring relaxation assays; in vivo blood pressure measurements","journal":"European journal of histochemistry; British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout mice with functional vascular readouts and co-localization data, two independent studies","pmids":["15590415","20067476"],"is_preprint":false},{"year":2004,"finding":"NTPDase1 coexpression dramatically reduces P2Y1 receptor activation potency (50-fold increase in EC50 for ADP), while NTPDase2 increases apparent ATP potency at P2Y1R by converting ATP to ADP. Basal P2Y1 receptor activity is maintained by paracrine/autocrine nucleotide release and is abolished by NTPDase1.","method":"Co-expression of NTPDase1 or NTPDase2 with P2Y1R in same cell or co-culture; phospholipase C activity assays; comparison of agonist EC50 values","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic co-expression experiment with quantitative EC50 measurements, single lab","pmids":["15496502"],"is_preprint":false},{"year":2014,"finding":"RhoA signaling downstream of platelet P2Y1 receptor (not P2Y12 or P2X1) mediates platelet-dependent leukocyte recruitment in allergic inflammation. P2Y1 receptor stimulation activated RhoA in vivo after allergen challenge, and ROCK1 inhibition in platelets phenocopied P2Y1 antagonism in preventing platelet-dependent leukocyte chemotaxis.","method":"Selective P2Y1 antagonist in ovalbumin-sensitized BALB/c mice; thrombocytopenia reinfusion experiments with P2Y1-antagonist or ROCK1-inhibitor pretreated platelets; RhoA activity assays; bronchoalveolar lavage cell counts","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — platelet reinfusion experiments establishing platelet-intrinsic P2Y1-RhoA pathway, selective pharmacology with multiple controls","pmids":["25445826"],"is_preprint":false},{"year":2008,"finding":"ADP stimulates human endothelial cell migration via P2Y1 receptor-mediated activation of ERK1/2, JNK, and p38 MAPK pathways. Blockade of ERK or JNK (but partial inhibition with p38 blockade) abolished ADP/2-MeSADP-stimulated HUVEC migration. This was blocked by MRS2179 (P2Y1 antagonist) but not AR-C69931MX (P2Y12/13 antagonist).","method":"Boyden chamber and wound-repair migration assays; RT-PCR for receptor expression; phospho-specific Western blots; selective MAPK inhibitors (U0126, SP600125, SB203580); selective P2Y1 antagonist","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional migration assay with pathway dissection using multiple selective inhibitors, single lab","pmids":["18174464"],"is_preprint":false},{"year":2007,"finding":"P2Y1 receptor in epithelial cells transactivates EGFR to broadcast mitogenic signals via PKC, Src, and cell surface metalloproteases. P2Y1R stimulation for 15–60 min triggered proliferation; apyrase degradation of extracellular nucleotides or P2Y1R drug inhibition reduced basal cell proliferation. MDCK cells ectopically expressing P2Y1R showed a highly proliferative EGFR-dependent phenotype with increased EGFR levels.","method":"Apyrase treatment; P2Y1R pharmacological inhibition; ectopic P2Y1R expression in MDCK cells; PKC/Src/metalloprotease inhibitors; cell proliferation assays","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ectopic expression with pharmacological pathway dissection, single lab with multiple inhibitors","pmids":["18057028"],"is_preprint":false},{"year":2008,"finding":"P2Y1 receptor signaling in pancreatic beta cells contributes to glucose-induced pulsatile insulin secretion through autocrine activation following ATP exocytosis, generating plasma membrane DAG spikes in spatially confined microdomains. Each DAG spike causes local PKC activation and MARCKS dissociation from the plasma membrane. Inhibition of P2Y1 suppressed glucose-induced pulsatile insulin secretion.","method":"TIRF microscopy with DAG/PKC translocation biosensors; insulin secretion assay; P2Y1/P2X receptor inhibitors; exocytosis inhibition; MIN6 cells, primary mouse, and human beta cells","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live imaging biosensors with pharmacological dissection in three cell types, single lab","pmids":["23299857"],"is_preprint":false},{"year":2013,"finding":"Polyphosphate amplifies proinflammatory responses of histone H4 and HMGB1 specifically through RAGE and P2Y1 receptor interaction in human umbilical vein endothelial cells, eliciting intracellular Ca2+ release. siRNA knockdown of P2Y1 and extracellular domain competitive inhibition demonstrated P2Y1 is required for polyP-mediated H4/HMGB1 inflammatory signaling.","method":"siRNA knockdown of TLR2, TLR4, RAGE, P2Y1; competitive inhibition with extracellular receptor domains; calcium release assays; in vivo inflammatory models","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA plus competitive inhibition identifying specific receptor, multiple controls, single lab","pmids":["24255918"],"is_preprint":false},{"year":2003,"finding":"P2Y12 receptor (not P2Y1) is involved in thrombin-induced phosphatidylserine (PS) exposure on platelets and subsequent TF-induced thrombin generation in platelet-rich plasma. Both P2Y1 and P2Y12 contribute to platelet-leukocyte interactions and leukocyte TF exposure via P-selectin.","method":"Selective P2 antagonists MRS2179 (P2Y1) and AR-C69931MX (P2Y12); PS exposure assay; thrombin generation in platelet-rich plasma; platelet-leukocyte complex formation","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective pharmacological dissection in native human platelets, single lab with defined endpoints","pmids":["12933533"],"is_preprint":false},{"year":2003,"finding":"P2Y1 receptor mediates ADP-induced p38 MAP kinase-activating factor generation in human platelets. The P2Y1-selective antagonist A2P5P inhibited ADP-induced p38 kinase activation in a concentration-dependent manner, while the P2TAC (P2Y12) antagonist AR-C66096 did not, and P2X1-selective agonist alphabeta-meATP failed to activate p38.","method":"Selective P2Y1 antagonist (A2P5P) and P2Y12 antagonist (AR-C66096); p38 MAP kinase phosphorylation assay; aspirin-treated vs normal platelets; TX synthase inhibitor controls","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with selective antagonists in native platelets, single lab","pmids":["10759852"],"is_preprint":false},{"year":2011,"finding":"P2Y1 receptor is required for normal thermal sensitivity in cutaneous polymodal nociceptors (CPMs). P2Y1-/- mice showed significantly increased heat thresholds and decreased peak firing rates during thermal ramp stimulation, and altered cold thresholds, with no significant change in mechanical sensitivity. Most ADP-responsive DRG neurons co-express IB4 binding and P2X3.","method":"P2Y1 knockout mice; ex vivo skin-nerve-DRG-spinal cord recording preparation; ratiometric calcium imaging of isolated DRG neurons; digital thermal and mechanical stimuli","journal":"Molecular pain","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with direct electrophysiological recording from identified cell types and specific thermal/mechanical stimulus protocols","pmids":["21310055"],"is_preprint":false},{"year":2011,"finding":"Inflammation-induced upregulation of P2Y1 receptor in DRG neurons is required for CFA-induced heat sensitization of cutaneous CPM fibers. siRNA knockdown of the P2Y1 increase during inflammation completely blocked the normal reduction of heat thresholds. P2Y1 knockdown also increased TRPV1-expressing CPM neurons without changing total TRPV1+ cells, indicating P2Y1 maintains phenotype in cutaneous TRPV1-negative afferents.","method":"In vivo siRNA knockdown targeting DRG P2Y1; CFA-induced inflammation; ex vivo electrophysiological recording; immunohistochemistry for TRPV1 expression","journal":"Pain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo siRNA with electrophysiological and phenotypic readouts, single lab","pmids":["22137295"],"is_preprint":false},{"year":2003,"finding":"Reduced P2Y1 receptor expression in Cx43-null neural progenitor neurospheres impairs calcium signaling in response to P2Y (but not P2X) agonists, and reduces proliferation and migration of neural progenitors. Ectopic expression of P2Y1R in Cx43-null cells restored migration to wild-type levels.","method":"Connexin43 knockout mice-derived neurospheres; pharmacological blockade with MRS-2179 and suramin; P2Y1R rescue by ectopic expression; calcium imaging; BrdU proliferation assay; migration assay","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — rescue by ectopic expression combined with genetic knockout and pharmacological blockade, single lab","pmids":["14673009"],"is_preprint":false},{"year":2017,"finding":"BPTU (allosteric P2Y1R antagonist binding outside the helical bundle) antagonizes P2Y1R in a pattern that varies by signaling pathway and agonist used: surmountable (parallel rightward shift, unaffected Emax) for ERK1/2 and label-free readouts with 5'-diphosphate agonists, but insurmountable (suppressed Emax) for GTPgammaS binding and beta-arrestin2 recruitment, and insurmountable in all pathways with dinucleotide Ap4A. Orthosteric MRS2500 behaves as surmountable antagonist across all pathways and agonists.","method":"Multiple signaling assays (ERK1/2, GTPgammaS binding, beta-arrestin2 recruitment, label-free dynamic mass redistribution); concentration-response curve analysis with diverse agonists","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling pathway readouts with two antagonists and three agonists, single lab","pmids":["28864555"],"is_preprint":false},{"year":2008,"finding":"Mechanical stress in human periodontal ligament cells induces ATP release, which activates P2Y1 receptor to stimulate Rho kinase activation and subsequent osteopontin (OPN) expression upregulation. Selective P2Y1 antagonist MRS2179 and apyrase abolished stress-induced OPN expression.","method":"Mechanical stress stimulation; P2Y1 antagonist (MRS2179); apyrase; Rho kinase inhibitor; RT-PCR and Western blot for OPN","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective antagonist and enzymatic nucleotide degradation controls, single lab","pmids":["18502966"],"is_preprint":false},{"year":2010,"finding":"Extracellular ATP stimulates RANKL expression in human periodontal ligament cells through P2Y1 receptor via a COX-dependent pathway involving cAMP-dependent PKA, NF-κB activation, and prostaglandin E2 production. P2Y1 siRNA and the selective antagonist MRS2179 both diminished this effect.","method":"P2Y1 siRNA; selective antagonist MRS2179; COX inhibitor indomethacin; PKA inhibitor H89; NF-κB inhibitor; PGE2 ELISA; RANKL RT-PCR and Western blot","journal":"Journal of periodontal research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA plus pharmacological inhibition of multiple pathway components, single lab","pmids":["20337886"],"is_preprint":false},{"year":2007,"finding":"A1 adenosine receptor and P2Y1 receptor co-localize at synaptic membranes and surrounding astroglial membranes of glutamatergic synapses in rat hippocampus. Functionally, P2Y1 receptor stimulation impairs A1 receptor coupling to G protein, while A1 receptor stimulation increases P2Y1 receptor functional responsiveness.","method":"Postembedding immunogold electron microscopy; G protein coupling assays after receptor co-stimulation in hippocampal tissue","journal":"The European journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — immunogold EM co-localization with functional G-protein coupling assays, single lab","pmids":["17672857"],"is_preprint":false}],"current_model":"P2Y1R is a Gq-coupled GPCR activated by extracellular ADP (and related dinucleotides) with two structurally characterized ligand-binding sites—an orthosteric transmembrane site and an allosteric site on the receptor–lipid bilayer interface; upon ADP binding it breaks an ionic lock and opens a water channel to activate Gq, stimulating PLC-IP3-Ca2+ mobilization, PKC, ERK1/2, JNK, and Rac/RhoA pathways; its activity is terminated by PKC-dependent desensitization, ALIX/YPX3L-mediated ubiquitin-independent lysosomal sorting, and SNX1-regulated slow recycling; it forms constitutive and agonist-induced homodimers (requiring the C-terminal DTSL motif and NHERF-2 scaffold) and hetero-oligomers with P2Y11 that redirect P2Y11 internalization and ligand selectivity; in platelets P2Y1R is essential for ADP-induced shape change, aggregation, Rac activation, and Ca2+ mobilization (with P2Y12 providing the complementary adenylyl cyclase-inhibitory limb); in astrocytes it triggers glutamate exocytosis, inhibits GABA transport, and mediates Ca2+ wave propagation; in the enteric nervous system it transduces purinergic inhibitory neurotransmission controlling colonic motility; and in sensory neurons it regulates thermal nociception and undergoes inflammation-induced upregulation that drives heat sensitization."},"narrative":{"mechanistic_narrative":"P2RY1 (P2Y1R) is a Gq-coupled G-protein-coupled receptor for extracellular ADP that converts purinergic signals into PLC-IP3-Ca2+ mobilization and broad downstream kinase activation across platelets, vasculature, and the nervous system [PMID:9038354, PMID:14742685, PMID:11278310]. Reconstitution of purified receptor with heterotrimeric Gq confirms direct agonist-stimulated GTP hydrolysis with the rank order 2MeSADP > ADP >> ATP, establishing ADP as the physiological full agonist and ATP as a low-potency partial agonist/competitive antagonist [PMID:9547364, PMID:14742685]. Crystallography resolved two distinct ligand pockets—an orthosteric site within the transmembrane bundle occupied by nucleotide antagonists and an allosteric pocket on the receptor–lipid interface bound by BPTU—and these sites translate into distinct, pathway-dependent antagonist pharmacology [PMID:25822790, PMID:28864555]. Downstream of Gq, P2Y1R drives ERK1/2, JNK, and p38 signaling to Elk-1-dependent transcription, Rac/RhoA-dependent cytoskeletal remodeling, and EGFR transactivation [PMID:11278310, PMID:12805285, PMID:16194206, PMID:18057028]. Receptor activity is shaped at multiple levels: ectonucleotidases (NTPDase1/2) set local agonist availability and desensitization state [PMID:15590415, PMID:20067476, PMID:15496502], PKC mediates desensitization and frequency-dependent negative feedback via C-terminal Thr339 [PMID:15665114, PMID:12805284], and trafficking is governed by ALIX/YPX3L-directed ubiquitin-independent lysosomal sorting and SNX1-regulated slow recycling [PMID:27301021, PMID:20070609]. The receptor constitutively homodimerizes through a C-terminal DTSL/NHERF-2 interaction required for internalization, and hetero-oligomerizes with P2Y11 to redirect its trafficking and ligand selectivity [PMID:17824841, PMID:18270199]. Physiologically, P2Y1R is essential and non-redundant for ADP-induced platelet shape change, aggregation, Ca2+ mobilization, and Rac/RhoA activation, while a separate receptor (P2Y12) couples ADP to adenylyl cyclase inhibition [PMID:9639511, PMID:16194206, PMID:11341507]; it mediates fast inhibitory purinergic neurotransmission controlling colonic motility [PMID:22371476, PMID:25341729], astrocytic glutamate exocytosis and GABA-transporter regulation [PMID:16882655, PMID:24733747], and thermal nociception, undergoing inflammation-induced upregulation that drives heat sensitization [PMID:21310055, PMID:22137295].","teleology":[{"year":1997,"claim":"Established the molecular identity of the platelet ADP receptor by showing the cloned P2Y1 receptor is an ADP-activated, calcium-mobilizing GPCR, resolving which gene transduces ADP-evoked Ca2+ signals.","evidence":"Heterologous expression in Jurkat cells with HPLC-purified nucleotide pharmacology and platelet RT-PCR","pmids":["9038354"],"confidence":"High","gaps":["Did not resolve which receptor couples ADP to adenylyl cyclase inhibition","Coupling partner (Gq) inferred pharmacologically, not biochemically"]},{"year":1998,"claim":"Clarified the true agonist/antagonist profile by removing nucleotide contamination, demonstrating ADP is the full agonist and ATP a competitive antagonist, and that selective antagonists block platelet aggregation/Ca2+ but not adenylyl cyclase inhibition—splitting the platelet ADP response into two receptors.","evidence":"Purity-controlled pharmacology in endothelial and Jurkat cells, plus selective antagonists in human platelets with fura-2 imaging","pmids":["9547364","9639511"],"confidence":"High","gaps":["Identity of the second adenylyl-cyclase-coupled ADP receptor not yet established","Antagonist binding residues not mapped"]},{"year":1998,"claim":"Localized the antagonist/nucleotide binding determinants to specific transmembrane residues, providing the first structural model of where ligands engage the receptor.","evidence":"Site-directed mutagenesis with PLC functional readout and rhodopsin-based molecular modeling","pmids":["9554879"],"confidence":"High","gaps":["Model based on rhodopsin homology, not direct structure","Agonist binding mode not resolved"]},{"year":2001,"claim":"Defined the downstream kinase architecture, showing P2Y1R activates ERK1/2 and JNK (but not p38) through PI3K/Src/PKC-Ras inputs converging on Elk-1, with a JNK limb driving apoptosis.","evidence":"Dominant-negative Ras/MKK4, kinase inhibitors, pertussis toxin, and caspase-3 assays in stable cell lines","pmids":["11278310"],"confidence":"High","gaps":["Cell-type generality of the apoptotic JNK limb unclear","Direct effector linkages inferred pharmacologically"]},{"year":2004,"claim":"Proved direct Gq coupling biochemically by reconstituting purified receptor with heterotrimeric Gq, fixing the agonist rank order under conditions that prevent nucleotide metabolism.","evidence":"Receptor purification from Sf9, proteoliposome reconstitution, radioligand binding, and steady-state GTPase assays","pmids":["14742685"],"confidence":"High","gaps":["Other G-protein couplings not tested in this system","Lipid/allosteric modulation not addressed"]},{"year":2004,"claim":"Revealed an intrinsic voltage sensitivity of P2Y1R that potentiates IP3-dependent Ca2+ release independent of voltage-gated channels, expanding the receptor's signaling repertoire.","evidence":"Patch clamp with fura-2 in megakaryocytes from P2Y1-knockout mice, with GTPgammaS/AlF4- dialysis controls","pmids":["15528188"],"confidence":"High","gaps":["Structural basis of voltage sensing not identified","Physiological relevance outside megakaryocytes unclear"]},{"year":2005,"claim":"Distinguished P2Y1 desensitization mechanism from P2Y12, showing it is PKC-dependent rather than GRK-mediated.","evidence":"Dominant-negative GRK, GRK siRNA, and PKC inhibition in platelets and 1321N1 cells","pmids":["15665114"],"confidence":"High","gaps":["PKC phosphorylation site(s) not yet mapped here","Arrestin involvement not directly assessed"]},{"year":2005,"claim":"Assigned the Rac-activating limb of platelet ADP signaling to P2Y1R via Gq, linking the receptor to PAK and actin polymerization independently of P2Y12 and PI3K.","evidence":"Rac-GTP pulldowns, selective antagonists, P2Y1-knockout platelets, and PAK/actin assays","pmids":["16194206"],"confidence":"High","gaps":["Identity of the GEF coupling Gq to Rac not defined"]},{"year":2008,"claim":"Mapped the determinants of receptor oligomerization and trafficking, showing constitutive/agonist-induced homodimerization via the C-terminal DTSL motif and NHERF-2 is required for internalization but not activation, and that P2Y1 hetero-oligomerizes with P2Y11 to control its endocytosis and ligand selectivity.","evidence":"Live-cell FRET, C-terminal deletion mutants, co-IP/co-pulldown, and siRNA rescue in HEK293/1321N1 cells","pmids":["18270199","17824841"],"confidence":"High","gaps":["Stoichiometry of higher-order oligomers unresolved","In vivo relevance of P2Y1-P2Y11 heteromers not shown"]},{"year":2016,"claim":"Defined the post-activation degradative fate of P2Y1R as a ubiquitin-independent ALIX/YPX3L-dependent lysosomal sorting pathway, complementing an earlier SNX1-regulated slow recycling route.","evidence":"ALIX siRNA, YPX3L motif mutagenesis, and degradation/recycling microscopy; SNX1 and retromer manipulation","pmids":["27301021","20070609"],"confidence":"Medium","gaps":["Switch between recycling and degradation fates not defined","Single-lab findings for each trafficking route"]},{"year":2015,"claim":"Provided atomic-resolution structures revealing two spatially distinct ligand pockets—orthosteric (intra-helical) and allosteric (lipid-interface)—establishing a structural basis for the receptor's dual antagonist pharmacology.","evidence":"X-ray crystallography of MRS2500 and BPTU complexes, with all-atom MD simulations of the activation mechanism","pmids":["25822790","27460867"],"confidence":"High","gaps":["No active-state agonist-bound or Gq-coupled structure","MD activation model lacks mutagenesis validation"]},{"year":2017,"claim":"Demonstrated that allosteric vs orthosteric antagonism produces pathway- and agonist-biased blockade, refining how the two binding sites translate into functional pharmacology.","evidence":"ERK1/2, GTPgammaS, beta-arrestin2, and label-free assays with multiple agonists and antagonists","pmids":["28864555"],"confidence":"Medium","gaps":["Structural basis of probe dependence not resolved","Single-lab dataset"]},{"year":2014,"claim":"Identified physiological purinergic neurotransmitters and gut function for P2Y1R, showing it mediates fast inhibitory junction potentials and Up4A-evoked relaxation controlling colonic motility.","evidence":"P2ry1-knockout mice with intracellular electrophysiology, contractility, transit imaging, and heterologous Ca2+ assays","pmids":["22371476","25341729"],"confidence":"High","gaps":["Source and regulation of endogenous beta-NAD/Up4A release not fully defined"]},{"year":2014,"claim":"Established astrocytic and glial roles for P2Y1R, coupling it to regulated glutamate exocytosis (via TNFalpha/PGE2), GABA-transporter inhibition, and PKC-gated Ca2+ oscillation feedback at C-terminal Thr339.","evidence":"TIRF vesicle imaging, knockout mice, PLC/Ca2+ chelation controls, and C-terminal mutagenesis in primary astrocytes","pmids":["16882655","24733747","12805284"],"confidence":"High","gaps":["Integration of these glial outputs in intact circuits incompletely defined"]},{"year":2011,"claim":"Defined a sensory role, showing P2Y1R is required for normal thermal nociceptor sensitivity and that inflammation-driven upregulation mediates heat sensitization.","evidence":"P2Y1-knockout mice and in vivo DRG siRNA with ex vivo skin-nerve recording and DRG calcium imaging","pmids":["21310055","22137295"],"confidence":"High","gaps":["Molecular link between P2Y1 and TRPV1-channel modulation not fully resolved","Inflammation upregulation mechanism not defined"]},{"year":null,"claim":"How the two structurally defined ligand sites, oligomerization state, and ectonucleotidase-set agonist microenvironment integrate to dictate biased signaling and tissue-specific output in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No active-state structure with Gq","No unified model linking dimerization/heteromerization to signaling bias in native tissue","Determinants of recycling-vs-degradation fate undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,6,3]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[24,11,8]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[9]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[9,10]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,6,13]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[4,20,19]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[15,16,33]}],"complexes":[],"partners":["P2RY11","NHERF2","PDCD6IP","SNX1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P47900","full_name":"P2Y purinoceptor 1","aliases":["ADP receptor","Purinergic receptor"],"length_aa":373,"mass_kda":42.1,"function":"Receptor for extracellular adenine nucleotides such as ADP (PubMed:25822790, PubMed:9038354, PubMed:9442040). In platelets, binding to ADP leads to mobilization of intracellular calcium ions via activation of phospholipase C, a change in platelet shape, and ultimately platelet aggregation (PubMed:9442040)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P47900/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/P2RY1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/P2RY1","total_profiled":1310},"omim":[{"mim_id":"621003","title":"TRANSCRIPTION FACTOR Sp9; SP9","url":"https://www.omim.org/entry/621003"},{"mim_id":"618925","title":"G PROTEIN-COUPLED RECEPTOR 171; GPR171","url":"https://www.omim.org/entry/618925"},{"mim_id":"602697","title":"PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 11; P2RY11","url":"https://www.omim.org/entry/602697"},{"mim_id":"602451","title":"PYRIMIDINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 6; P2RY6","url":"https://www.omim.org/entry/602451"},{"mim_id":"601167","title":"PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 1; P2RY1","url":"https://www.omim.org/entry/601167"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":23.9}],"url":"https://www.proteinatlas.org/search/P2RY1"},"hgnc":{"alias_symbol":["P2Y1","SARCC"],"prev_symbol":[]},"alphafold":{"accession":"P47900","domains":[{"cath_id":"1.20.1070.10","chopping":"50-327","consensus_level":"high","plddt":93.6659,"start":50,"end":327}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P47900","model_url":"https://alphafold.ebi.ac.uk/files/AF-P47900-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P47900-F1-predicted_aligned_error_v6.png","plddt_mean":85.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=P2RY1","jax_strain_url":"https://www.jax.org/strain/search?query=P2RY1"},"sequence":{"accession":"P47900","fasta_url":"https://rest.uniprot.org/uniprotkb/P47900.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P47900/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P47900"}},"corpus_meta":[{"pmid":"25822790","id":"PMC_25822790","title":"Two disparate ligand-binding sites in the human P2Y1 receptor.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25822790","citation_count":288,"is_preprint":false},{"pmid":"9038354","id":"PMC_9038354","title":"The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9038354","citation_count":239,"is_preprint":false},{"pmid":"8913364","id":"PMC_8913364","title":"Identification of competitive antagonists of the P2Y1 receptor.","date":"1996","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8913364","citation_count":225,"is_preprint":false},{"pmid":"9639511","id":"PMC_9639511","title":"The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9639511","citation_count":206,"is_preprint":false},{"pmid":"16882655","id":"PMC_16882655","title":"P2Y1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and prostaglandins.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16882655","citation_count":177,"is_preprint":false},{"pmid":"9554879","id":"PMC_9554879","title":"Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites.","date":"1998","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9554879","citation_count":140,"is_preprint":false},{"pmid":"28644440","id":"PMC_28644440","title":"LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28644440","citation_count":137,"is_preprint":false},{"pmid":"15665114","id":"PMC_15665114","title":"P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15665114","citation_count":133,"is_preprint":false},{"pmid":"9547364","id":"PMC_9547364","title":"ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor.","date":"1998","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9547364","citation_count":117,"is_preprint":false},{"pmid":"14564529","id":"PMC_14564529","title":"Localisation of P2Y1 and P2Y4 receptors in dorsal root, nodose and trigeminal ganglia of the rat.","date":"2003","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14564529","citation_count":115,"is_preprint":false},{"pmid":"8579591","id":"PMC_8579591","title":"Cloning and chromosomal localization of the human P2Y1 purinoceptor.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8579591","citation_count":115,"is_preprint":false},{"pmid":"9457242","id":"PMC_9457242","title":"Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors.","date":"1998","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9457242","citation_count":111,"is_preprint":false},{"pmid":"12933533","id":"PMC_12933533","title":"Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12933533","citation_count":108,"is_preprint":false},{"pmid":"14673009","id":"PMC_14673009","title":"Reduced expression of P2Y1 receptors in connexin43-null mice alters calcium signaling and migration of neural progenitor cells.","date":"2003","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/14673009","citation_count":106,"is_preprint":false},{"pmid":"22371476","id":"PMC_22371476","title":"P2Y1 purinoreceptors are fundamental to inhibitory motor control of murine colonic excitability and transit.","date":"2012","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22371476","citation_count":104,"is_preprint":false},{"pmid":"15514209","id":"PMC_15514209","title":"Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15514209","citation_count":100,"is_preprint":false},{"pmid":"14742685","id":"PMC_14742685","title":"Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor.","date":"2004","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14742685","citation_count":98,"is_preprint":false},{"pmid":"29724785","id":"PMC_29724785","title":"P2Y1 receptor blockade normalizes network dysfunction and cognition in an Alzheimer's disease model.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29724785","citation_count":96,"is_preprint":false},{"pmid":"24255918","id":"PMC_24255918","title":"Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24255918","citation_count":96,"is_preprint":false},{"pmid":"11278310","id":"PMC_11278310","title":"Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and induce apoptosis.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278310","citation_count":91,"is_preprint":false},{"pmid":"9630355","id":"PMC_9630355","title":"P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.","date":"1998","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9630355","citation_count":89,"is_preprint":false},{"pmid":"20681951","id":"PMC_20681951","title":"TGF-β and LPS modulate ADP-induced migration of microglial cells through P2Y1 and P2Y12 receptor expression.","date":"2010","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20681951","citation_count":86,"is_preprint":false},{"pmid":"8630005","id":"PMC_8630005","title":"Cloning and tissue distribution of the human P2Y1 receptor.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8630005","citation_count":82,"is_preprint":false},{"pmid":"12970084","id":"PMC_12970084","title":"P2X4, P2Y1 and P2Y2 receptors on rat alveolar macrophages.","date":"2003","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12970084","citation_count":82,"is_preprint":false},{"pmid":"17824841","id":"PMC_17824841","title":"Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor.","date":"2008","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17824841","citation_count":81,"is_preprint":false},{"pmid":"29463792","id":"PMC_29463792","title":"Glutamate-induced and NMDA receptor-mediated neurodegeneration entails P2Y1 receptor activation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29463792","citation_count":76,"is_preprint":false},{"pmid":"12805284","id":"PMC_12805284","title":"Differential frequency dependence of P2Y1- and P2Y2- mediated Ca 2+ signaling in astrocytes.","date":"2003","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12805284","citation_count":73,"is_preprint":false},{"pmid":"18174464","id":"PMC_18174464","title":"ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways.","date":"2008","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/18174464","citation_count":72,"is_preprint":false},{"pmid":"26973243","id":"PMC_26973243","title":"Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26973243","citation_count":66,"is_preprint":false},{"pmid":"12805285","id":"PMC_12805285","title":"ATP acts via P2Y1 receptors to stimulate acetylcholinesterase and acetylcholine receptor expression: transduction and transcription control.","date":"2003","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12805285","citation_count":64,"is_preprint":false},{"pmid":"18596227","id":"PMC_18596227","title":"A molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 activation.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18596227","citation_count":64,"is_preprint":false},{"pmid":"15452043","id":"PMC_15452043","title":"Expression of P2Y1, P2Y2, P2Y4, and P2Y6 receptor subtypes in the rat retina.","date":"2004","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/15452043","citation_count":60,"is_preprint":false},{"pmid":"25445826","id":"PMC_25445826","title":"RhoA signaling through platelet P2Y₁ receptor controls leukocyte recruitment in allergic mice.","date":"2014","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25445826","citation_count":60,"is_preprint":false},{"pmid":"11004484","id":"PMC_11004484","title":"Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11004484","citation_count":58,"is_preprint":false},{"pmid":"11543678","id":"PMC_11543678","title":"Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking.","date":"2001","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11543678","citation_count":57,"is_preprint":false},{"pmid":"19637098","id":"PMC_19637098","title":"Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.","date":"2009","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/19637098","citation_count":56,"is_preprint":false},{"pmid":"15888248","id":"PMC_15888248","title":"P2Y1 and cysteinyl leukotriene receptors mediate purine and cysteinyl leukotriene co-release in primary cultures of rat microglia.","date":"2005","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15888248","citation_count":56,"is_preprint":false},{"pmid":"10229631","id":"PMC_10229631","title":"Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists.","date":"1999","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10229631","citation_count":56,"is_preprint":false},{"pmid":"20962269","id":"PMC_20962269","title":"P2Y1 and P2Y13 purinergic receptors mediate Ca2+ signaling and proliferative responses in pulmonary artery vasa vasorum endothelial cells.","date":"2010","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20962269","citation_count":51,"is_preprint":false},{"pmid":"11117494","id":"PMC_11117494","title":"Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer's disease.","date":"2000","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/11117494","citation_count":51,"is_preprint":false},{"pmid":"15528188","id":"PMC_15528188","title":"Direct voltage control of signaling via P2Y1 and other Galphaq-coupled receptors.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15528188","citation_count":51,"is_preprint":false},{"pmid":"9517568","id":"PMC_9517568","title":"ATP-induced arachidonic acid release in cultured astrocytes is mediated by Gi protein coupled P2Y1 and P2Y2 receptors.","date":"1998","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/9517568","citation_count":51,"is_preprint":false},{"pmid":"27301021","id":"PMC_27301021","title":"ALIX Regulates the Ubiquitin-Independent Lysosomal Sorting of the P2Y1 Purinergic Receptor via a YPX3L Motif.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27301021","citation_count":50,"is_preprint":false},{"pmid":"20024498","id":"PMC_20024498","title":"Toll-like receptor 2 stimulation of platelets is mediated by purinergic P2X1-dependent Ca2+ mobilisation, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activation.","date":"2009","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/20024498","citation_count":50,"is_preprint":false},{"pmid":"29490276","id":"PMC_29490276","title":"P2RY1/ALK3-Expressing Cells within the Adult Human Exocrine Pancreas Are BMP-7 Expandable and Exhibit Progenitor-like Characteristics.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29490276","citation_count":48,"is_preprint":false},{"pmid":"18502966","id":"PMC_18502966","title":"Mechanical stress induces osteopontin via ATP/P2Y1 in periodontal cells.","date":"2008","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/18502966","citation_count":48,"is_preprint":false},{"pmid":"12694404","id":"PMC_12694404","title":"Characterization of P2X3, P2Y1 and P2Y4 receptors in cultured HEK293-hP2X3 cells and their inhibition by ethanol and trichloroethanol.","date":"2003","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12694404","citation_count":48,"is_preprint":false},{"pmid":"12595918","id":"PMC_12595918","title":"The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179.","date":"2003","source":"Cardiovascular drug reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12595918","citation_count":47,"is_preprint":false},{"pmid":"27460867","id":"PMC_27460867","title":"The Molecular Mechanism of P2Y1 Receptor Activation.","date":"2016","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/27460867","citation_count":46,"is_preprint":false},{"pmid":"20070609","id":"PMC_20070609","title":"Regulation of P2Y1 receptor traffic by sorting Nexin 1 is retromer independent.","date":"2010","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/20070609","citation_count":46,"is_preprint":false},{"pmid":"15103469","id":"PMC_15103469","title":"Expression of P2Y1 receptors in rat taste buds.","date":"2004","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15103469","citation_count":45,"is_preprint":false},{"pmid":"11341507","id":"PMC_11341507","title":"Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation.","date":"2001","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11341507","citation_count":45,"is_preprint":false},{"pmid":"24733747","id":"PMC_24733747","title":"P2Y1 receptor inhibits GABA transport through a calcium signalling-dependent mechanism in rat cortical astrocytes.","date":"2014","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/24733747","citation_count":44,"is_preprint":false},{"pmid":"16819989","id":"PMC_16819989","title":"P2Y1 and P2X7 receptors induce calcium/calmodulin-dependent protein kinase II phosphorylation in cerebellar granule neurons.","date":"2006","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16819989","citation_count":43,"is_preprint":false},{"pmid":"18057028","id":"PMC_18057028","title":"Nucleotide P2Y1 receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18057028","citation_count":43,"is_preprint":false},{"pmid":"23299857","id":"PMC_23299857","title":"P2Y₁ receptor-dependent diacylglycerol signaling microdomains in β cells promote insulin secretion.","date":"2013","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/23299857","citation_count":43,"is_preprint":false},{"pmid":"32508321","id":"PMC_32508321","title":"LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.","date":"2020","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/32508321","citation_count":42,"is_preprint":false},{"pmid":"26475857","id":"PMC_26475857","title":"P2Y1 Receptor Activation of the TRPV4 Ion Channel Enhances Purinergic Signaling in Satellite Glial Cells.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26475857","citation_count":42,"is_preprint":false},{"pmid":"17672857","id":"PMC_17672857","title":"Co-localization and functional cross-talk between A1 and P2Y1 purine receptors in rat hippocampus.","date":"2007","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17672857","citation_count":42,"is_preprint":false},{"pmid":"10759852","id":"PMC_10759852","title":"The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets.","date":"2000","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10759852","citation_count":41,"is_preprint":false},{"pmid":"25449358","id":"PMC_25449358","title":"Participation of peripheral P2Y1, P2Y6 and P2Y11 receptors in formalin-induced inflammatory pain in rats.","date":"2014","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/25449358","citation_count":41,"is_preprint":false},{"pmid":"20067476","id":"PMC_20067476","title":"The ecto-nucleotidase NTPDase1 differentially regulates P2Y1 and P2Y2 receptor-dependent vasorelaxation.","date":"2010","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20067476","citation_count":40,"is_preprint":false},{"pmid":"22137295","id":"PMC_22137295","title":"Purinergic receptor P2Y1 regulates polymodal C-fiber thermal thresholds and sensory neuron phenotypic switching during peripheral inflammation.","date":"2011","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/22137295","citation_count":40,"is_preprint":false},{"pmid":"16934758","id":"PMC_16934758","title":"Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16934758","citation_count":40,"is_preprint":false},{"pmid":"16194206","id":"PMC_16194206","title":"A differential role of the platelet ADP receptors P2Y1 and P2Y12 in Rac activation.","date":"2005","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/16194206","citation_count":40,"is_preprint":false},{"pmid":"21632028","id":"PMC_21632028","title":"Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21632028","citation_count":39,"is_preprint":false},{"pmid":"18668152","id":"PMC_18668152","title":"Effects of P2Y1 receptor on glial fibrillary acidic protein and glial cell line-derived neurotrophic factor production of astrocytes under ischemic condition and the related signaling pathways.","date":"2008","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/18668152","citation_count":38,"is_preprint":false},{"pmid":"31048325","id":"PMC_31048325","title":"Context-Specific Switch from Anti- to Pro-epileptogenic Function of the P2Y1 Receptor in Experimental Epilepsy.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31048325","citation_count":37,"is_preprint":false},{"pmid":"29305530","id":"PMC_29305530","title":"Role of Purinergic Receptor P2Y1 in Spatiotemporal Ca2+ Dynamics in Astrocytes.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29305530","citation_count":36,"is_preprint":false},{"pmid":"11336535","id":"PMC_11336535","title":"P2y1 and P2y2 receptor-operated Ca2+ signals in primary cultures of cardiac microvascular endothelial cells.","date":"2001","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/11336535","citation_count":35,"is_preprint":false},{"pmid":"18627435","id":"PMC_18627435","title":"P2Y1 receptor-mediated glutamate release from cultured dorsal spinal cord astrocytes.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18627435","citation_count":34,"is_preprint":false},{"pmid":"27788256","id":"PMC_27788256","title":"P2Y1 Receptor Signaling Contributes to High Salt-Induced Priming of the NLRP3 Inflammasome in Retinal Pigment Epithelial Cells.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27788256","citation_count":33,"is_preprint":false},{"pmid":"25341729","id":"PMC_25341729","title":"Uridine adenosine tetraphosphate is a novel neurogenic P2Y1 receptor activator in the gut.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25341729","citation_count":33,"is_preprint":false},{"pmid":"22721490","id":"PMC_22721490","title":"Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.","date":"2012","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/22721490","citation_count":33,"is_preprint":false},{"pmid":"26740646","id":"PMC_26740646","title":"Dual Modulation of Nociception and Cardiovascular Reflexes during Peripheral Ischemia through P2Y1 Receptor-Dependent Sensitization of Muscle Afferents.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26740646","citation_count":32,"is_preprint":false},{"pmid":"10066429","id":"PMC_10066429","title":"Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10066429","citation_count":32,"is_preprint":false},{"pmid":"18673269","id":"PMC_18673269","title":"Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor.","date":"2008","source":"Combinatorial chemistry & high throughput screening","url":"https://pubmed.ncbi.nlm.nih.gov/18673269","citation_count":31,"is_preprint":false},{"pmid":"12652343","id":"PMC_12652343","title":"Enhanced P2Y1 receptor expression in the brain after sensitisation with d-amphetamine.","date":"2003","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12652343","citation_count":31,"is_preprint":false},{"pmid":"20185765","id":"PMC_20185765","title":"The purinergic P2Y1 receptor supports leptin secretion in adipose tissue.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20185765","citation_count":31,"is_preprint":false},{"pmid":"15496502","id":"PMC_15496502","title":"Regulation of P2Y1 receptor-mediated signaling by the ectonucleoside triphosphate diphosphohydrolase isozymes NTPDase1 and NTPDase2.","date":"2004","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15496502","citation_count":31,"is_preprint":false},{"pmid":"18414379","id":"PMC_18414379","title":"Novel consequences of voltage-dependence to G-protein-coupled P2Y1 receptors.","date":"2008","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18414379","citation_count":31,"is_preprint":false},{"pmid":"28864555","id":"PMC_28864555","title":"Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor.","date":"2017","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28864555","citation_count":30,"is_preprint":false},{"pmid":"9142866","id":"PMC_9142866","title":"Changes in P2Y1 nucleotide receptor activity during the development of rat salivary glands.","date":"1997","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9142866","citation_count":30,"is_preprint":false},{"pmid":"22991416","id":"PMC_22991416","title":"Identification of contractile P2Y1, P2Y6, and P2Y12 receptors in rat intrapulmonary artery using selective ligands.","date":"2012","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22991416","citation_count":30,"is_preprint":false},{"pmid":"15197109","id":"PMC_15197109","title":"Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5'-O-(1-boranotriphosphate) derivatives.","date":"2004","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15197109","citation_count":30,"is_preprint":false},{"pmid":"16934527","id":"PMC_16934527","title":"The enteric purinergic P2Y1 receptor.","date":"2006","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16934527","citation_count":29,"is_preprint":false},{"pmid":"20337886","id":"PMC_20337886","title":"Adenosine triphosphate stimulates RANKL expression through P2Y1 receptor-cyclo-oxygenase-dependent pathway in human periodontal ligament cells.","date":"2010","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/20337886","citation_count":29,"is_preprint":false},{"pmid":"15590415","id":"PMC_15590415","title":"Co-localization of P2Y1 receptor and NTPDase1/CD39 within caveolae in human placenta.","date":"2004","source":"European journal of histochemistry : EJH","url":"https://pubmed.ncbi.nlm.nih.gov/15590415","citation_count":28,"is_preprint":false},{"pmid":"17215444","id":"PMC_17215444","title":"P2Y1 gene deficiency protects from renal disease progression and capillary rarefaction during passive crescentic glomerulonephritis.","date":"2007","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/17215444","citation_count":28,"is_preprint":false},{"pmid":"18270199","id":"PMC_18270199","title":"Constitutive and agonist-induced dimerizations of the P2Y1 receptor: relationship to internalization and scaffolding.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18270199","citation_count":28,"is_preprint":false},{"pmid":"26660522","id":"PMC_26660522","title":"The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys.","date":"2016","source":"Journal of thrombosis and thrombolysis","url":"https://pubmed.ncbi.nlm.nih.gov/26660522","citation_count":27,"is_preprint":false},{"pmid":"22349022","id":"PMC_22349022","title":"P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain.","date":"2012","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/22349022","citation_count":27,"is_preprint":false},{"pmid":"16953187","id":"PMC_16953187","title":"Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5'-O-(alpha-boranotriphosphate) analogues.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16953187","citation_count":27,"is_preprint":false},{"pmid":"20103587","id":"PMC_20103587","title":"P2Y1 receptors mediate apamin-sensitive and -insensitive inhibitory junction potentials in murine colonic circular smooth muscle.","date":"2010","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20103587","citation_count":27,"is_preprint":false},{"pmid":"16543271","id":"PMC_16543271","title":"P2Y1 and P2Y2 receptor distribution varies along the human placental vascular tree: role of nucleotides in vascular tone regulation.","date":"2006","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16543271","citation_count":26,"is_preprint":false},{"pmid":"17626796","id":"PMC_17626796","title":"Stimulation of the P2Y1 receptor up-regulates nucleoside-triphosphate diphosphohydrolase-1 in human retinal pigment epithelial cells.","date":"2007","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17626796","citation_count":26,"is_preprint":false},{"pmid":"30778022","id":"PMC_30778022","title":"MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes.","date":"2019","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/30778022","citation_count":25,"is_preprint":false},{"pmid":"20050186","id":"PMC_20050186","title":"P2X2, P2X4 and P2Y1 receptors elevate intracellular Ca2+ in mouse embryonic stem cell-derived GABAergic neurons.","date":"2009","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20050186","citation_count":24,"is_preprint":false},{"pmid":"21310055","id":"PMC_21310055","title":"The ADP receptor P2Y1 is necessary for normal thermal sensitivity in cutaneous polymodal nociceptors.","date":"2011","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/21310055","citation_count":24,"is_preprint":false},{"pmid":"25077539","id":"PMC_25077539","title":"Differential effects of P2Y1 deletion on glial activation and survival of photoreceptors and amacrine cells in the ischemic mouse retina.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25077539","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":58562,"output_tokens":10788,"usd":0.168753,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21712,"output_tokens":4943,"usd":0.116068,"stage2_stop_reason":"end_turn"},"total_usd":0.284821,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of human P2Y1R revealed two distinct ligand-binding sites: nucleotide antagonist MRS2500 binds within the seven transmembrane bundle (orthosteric site, distinct in shape and location from P2Y12R), while non-nucleotide antagonist BPTU binds an allosteric pocket on the external receptor–lipid bilayer interface entirely outside the helical bundle.\",\n      \"method\": \"X-ray crystallography at 2.7 Å (MRS2500 complex) and 2.2 Å (BPTU complex)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structures with two independent ligand complexes, replicated by subsequent MD simulations confirming functional relevance\",\n      \"pmids\": [\"25822790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"All-atom MD simulations (20 µs total) showed that ADP activates P2Y1R by breaking an ionic lock within the receptor and forming a continuous water channel, while BPTU acts as an antagonist by stabilizing extracellular helix bundles and increasing lipid order, and MRS2500 blocks signaling by occupying the orthosteric binding site.\",\n      \"method\": \"Long-timescale all-atom molecular dynamics simulations (20 µs)\",\n      \"journal\": \"Angewandte Chemie International Edition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 method (extensive MD) / Moderate — single computational study with mechanistic detail but no experimental mutagenesis validation reported in abstract\",\n      \"pmids\": [\"27460867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Human P2Y1 receptor expressed in Jurkat cells functions as an ADP receptor coupled to intracellular calcium mobilization; 2-methylthio-ADP is the most potent agonist, ADP is a full agonist, and ATP acts as a competitive antagonist. The receptor is expressed in platelets and megakaryoblastic cells, identifying it as the platelet P2T purinoceptor.\",\n      \"method\": \"Heterologous expression in Jurkat cells with HPLC-purified nucleotide agonist/antagonist pharmacology; RT-PCR in platelets and megakaryoblastic cell lines\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological characterization replicated across multiple labs and cell systems\",\n      \"pmids\": [\"9038354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"P2Y1 receptor is an ADP-specific Gq-coupled receptor; when ATP contamination is removed by creatine phosphate/creatine phosphokinase treatment, purified 2-MeSATP and 2-ClATP act as competitive antagonists (not agonists) at both rat and human P2Y1 receptors, demonstrating ATP is a competitive antagonist.\",\n      \"method\": \"Pharmacological assays with creatine phosphate/creatine phosphokinase nucleotide purity control in endothelial cells and P2Y1-transfected Jurkat cells\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous purity controls, replicated in two cell systems (endothelial and Jurkat), findings consistent with multiple other labs\",\n      \"pmids\": [\"9547364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Selective P2Y1 competitive antagonists A2P5P and A3P5P inhibit ADP-induced platelet shape change, aggregation, and calcium mobilization but do not affect ADP-induced inhibition of adenylyl cyclase in platelets, demonstrating P2Y1 is necessary for ADP-induced platelet aggregation and calcium mobilization but a separate ADP receptor couples to adenylyl cyclase.\",\n      \"method\": \"Pharmacological antagonism with selective P2Y1 antagonists in human platelets and P2Y1-expressing Jurkat cells; fura-2 calcium measurements\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — selective antagonists in native platelet system plus heterologous expression system, results replicated across labs\",\n      \"pmids\": [\"9639511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Site-directed mutagenesis of the human P2Y1 receptor identified key residues for antagonist binding: F226A, K280A, and Q307A mutations in transmembrane helices 5, 6, and 7 abolished antagonist MRS2179 potency; H132, T222, and Y136 had modulatory roles. A rhodopsin-based molecular model localized the nucleotide binding site to TM regions 3, 6, and 7.\",\n      \"method\": \"Site-directed mutagenesis of transmembrane domain residues combined with functional assay (phospholipase C stimulation) and computational molecular modeling\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with functional readout identifying specific binding residues in single lab, multiple mutations tested\",\n      \"pmids\": [\"9554879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Purified human P2Y1 receptor reconstituted in proteoliposomes with heterotrimeric Gq(alpha)beta1gamma2 directly stimulates GTP hydrolysis upon agonist addition (up to 50-fold with 2MeSADP plus RGS4). Agonist affinity order under conditions preventing nucleotide metabolism: 2MeSADP > ADP = 2MeSATP = ATPalphaS = ADPbetaS >> ATP. ATP is a partial agonist with 20-fold lower potency than ADP.\",\n      \"method\": \"Receptor purification from baculovirus/Sf9 system; reconstitution in proteoliposomes with purified heterotrimeric G proteins; radioligand binding ([3H]MRS2279); steady-state GTP hydrolysis\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution with purified proteins, multiple orthogonal methods (binding, GTPase, agonist rank order under controlled conditions)\",\n      \"pmids\": [\"14742685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"P2Y1 receptor desensitization in platelets and 1321N1 cells is mediated by protein kinase C, not by GRK2 or GRK6. In contrast, P2Y12 desensitization requires GRKs. Dominant-negative GRK mutants and GRK siRNA did not affect P2Y1 desensitization, while PKC inhibition abolished it.\",\n      \"method\": \"Dominant-negative GRK mutant overexpression; GRK-specific siRNA knockdown; PKC inhibition; platelet aggregation and calcium mobilization assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (dominant-negative, siRNA, pharmacological inhibition) in two cell systems\",\n      \"pmids\": [\"15665114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"P2Y11 receptor forms hetero-oligomers with P2Y1 receptor when co-expressed in HEK293 cells, detected by co-pulldown, co-immunoprecipitation, and FRET. This interaction promotes agonist-induced internalization of P2Y11 (which cannot undergo endocytosis alone), and alters the ligand selectivity of P2Y11. Endogenous P2Y1 in HEK293 cells supports GFP-P2Y11 endocytosis, abolished by P2Y1 siRNA.\",\n      \"method\": \"Co-pulldown, co-immunoprecipitation, FRET; siRNA knockdown; fluorescence microscopy of receptor internalization in 1321N1 and HEK293 cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, FRET, and siRNA rescue with functional consequence (internalization), multiple orthogonal methods\",\n      \"pmids\": [\"17824841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"After agonist activation, P2Y1 is sorted to lysosomes for degradation via a ubiquitin-independent pathway requiring a YPX3L motif in the second intracellular loop that binds the adaptor protein ALIX. Depletion of ALIX or mutation of the YPX3L motif blocks P2Y1 sorting into multivesicular endosome lumens and prevents lysosomal degradation.\",\n      \"method\": \"ALIX siRNA depletion; site-directed mutagenesis of YPX3L motif; fluorescence microscopy tracking lysosomal sorting; degradation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis of binding motif combined with siRNA knockdown and functional degradation assay in single lab\",\n      \"pmids\": [\"27301021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"P2Y1 receptor recycling occurs via a slow retromer-independent pathway regulated by sorting nexin 1 (SNX1). SNX1 inhibition dramatically increased the rate of P2Y1 receptor recycling, while inhibition of retromer components Vps26 and Vps35 had no effect. P2Y12 receptor returns to the cell surface via a rapid SNX1-independent route.\",\n      \"method\": \"SNX1 dominant-negative/knockdown; Vps26/Vps35 inhibition; fluorescence microscopy of receptor recycling kinetics\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown and negative controls distinguishing receptor-specific trafficking, single lab\",\n      \"pmids\": [\"20070609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"P2Y1 receptor constitutively dimerizes (44% of receptors as dimers at rest), with agonist exposure increasing dimerization to 85–100%; receptor dimers are required for internalization but not for activation. Removal of the C-terminal 19 amino acids abolished both dimerization and internalization; the last four amino acids (DTSL) mediate constitutive dimerization through binding to the scaffolding protein NHERF-2.\",\n      \"method\": \"FRET donor photobleaching in living HEK293 cells; C-terminal deletion mutants; functional assays for activation vs. internalization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — quantitative FRET in living cells with defined deletion mutants linking dimerization to specific C-terminal sequences and scaffolding protein, multiple mutants tested\",\n      \"pmids\": [\"18270199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Membrane depolarization potentiates IP3-dependent Ca2+ mobilization by P2Y1 receptor in megakaryocytes via a voltage sensitivity intrinsic to the receptor itself (not voltage-gated Ca2+ channels, G-protein betagamma subunits, or downstream signals). Megakaryocytes from P2Y1-/- mice lacked voltage-dependent Ca2+ release during ADP stimulation.\",\n      \"method\": \"Whole-cell patch clamp combined with fura-2 fluorescence in megakaryocytes; nifedipine controls; P2Y1 knockout mice; dialysis with GTPgammaS and AlF4-\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout combined with electrophysiology and pharmacological dissection in native cells, multiple controls ruling out alternative mechanisms\",\n      \"pmids\": [\"15528188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"P2Y1 receptor activation by 2-MeSADP stimulates ERK1/2 (EC50 ~5 nM) and selected SAPK/JNK isoforms but not p38 MAPK. Transient ERK activation involves cooperative effects of PI3K, Src, and PKC via Ras, while sustained ERK activation is Ras-independent and PI3K-dependent, culminating in Elk-1 phosphorylation. Transient SAPK activity via MKK4 is required for P2Y1-mediated apoptosis (caspase-3 activation). These responses are pertussis toxin-insensitive, indicating Gq-coupling.\",\n      \"method\": \"Selective kinase inhibitors; dominant-negative Ras and MKK4 mutants; pertussis toxin; phospho-specific Western blots; caspase-3 and cell number assays in stably expressing cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple dominant-negative constructs and pharmacological inhibitors in single lab with multiple orthogonal signaling readouts\",\n      \"pmids\": [\"11278310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"P2Y1 receptor activation by ATP in chick and mouse myotubes stimulates transcription of acetylcholinesterase and acetylcholine receptor subunit genes via a pathway involving PKC, intracellular Ca2+ release, ERK phosphorylation, and culminating in Elk-1 transcription factor activation. Two Elk-1 binding sites in the AChE promoter are sufficient to drive ATP-induced reporter gene transcription.\",\n      \"method\": \"Promoter-reporter constructs; dominant-negative and constitutively active kinase mutants; kinase inhibitors; gel mobility shift assays; nuclear phospho-Elk-1 immunostaining; P2Y1-selective antagonist blockade\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (reporter assays, dominant-negative constructs, EMSA, antagonist) in single lab\",\n      \"pmids\": [\"12805285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Selective activation of P2Y1 receptors in astrocytes triggers glutamate release by regulated exocytosis. The mechanism requires Ca2+ release from internal stores and is controlled by TNFalpha and PGE2: P2Y1R activation induces release of both TNFalpha and PGE2, and blocking either one significantly reduces glutamate release. Astrocytes from TNFalpha-/- or TNFR1-/- mice show deficient P2Y1R-dependent Ca2+ signaling and glutamate release.\",\n      \"method\": \"TIRF imaging of fluorescent glutamatergic vesicles; calcium imaging; TNFalpha/TNFR1 knockout mice; cyclooxygenase inhibitors; P2Y1-selective pharmacology; acute hippocampal slices\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct vesicle imaging, genetic knockout confirmation, pharmacological dissection, in vivo slice validation\",\n      \"pmids\": [\"16882655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"P2Y1 receptor (P2ry1) mediates the fast inhibitory junctional potential (fIJP) in murine colon via purinergic neurotransmission. P2ry1-/- mice completely lacked fIJPs and purinergic contractile responses. β-NAD and its metabolite ADPR caused P2Y1R-mediated hyperpolarization in wild-type but not P2ry1-/- mice. Colonic transit was significantly delayed in P2ry1-/- mice.\",\n      \"method\": \"P2ry1 knockout mice; electrophysiology (intracellular recordings); contractile experiments; picospritz neurotransmitter candidates; video imaging of colonic transit\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal functional readouts and pharmacological confirmation\",\n      \"pmids\": [\"22371476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Uridine adenosine tetraphosphate (Up4A) acts as a potent native agonist for P2Y1R in human and mouse colon muscles, causing relaxation and hyperpolarization via P2Y1R-SK channel activation. Up4A responses were blocked by MRS2500 and abolished in P2ry1-/- mice. Up4A induced MRS2500-sensitive Ca2+ transients in 1321N1 cells expressing human P2Y1R.\",\n      \"method\": \"P2ry1 knockout mice; isometric tension measurements; intracellular electrophysiology; isolated PDGFRα+ cells; heterologous expression calcium assays; HPLC metabolite analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout, multiple tissue preparations, heterologous expression, metabolite controls\",\n      \"pmids\": [\"25341729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"P2Y1 receptor is involved in ADP-stimulated microglial cell migration, in addition to P2Y12. Pharmacological inhibition and siRNA knockdown of P2Y1 reduced ADP-stimulated microglial migration. TGF-β treatment increased P2Y1 and P2Y12 expression and ADP-induced migration, while LPS abrogated both receptor expression and migration.\",\n      \"method\": \"P2Y1/P2Y12 selective pharmacological inhibitors; P2Y1 siRNA knockdown; microglial migration assay; calcium mobilization assays; qPCR for receptor expression\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological inhibition in primary microglia culture, single lab\",\n      \"pmids\": [\"20681951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"P2Y1 receptor mediates ADP-induced Rac GTPase activation via Gq-dependent pathway in platelets, independently of P2Y12 and GPIIb/IIIa and PI3K. P2Y12 receptor alone cannot activate Rac per se, but secreted ADP potentiates Rac activation from other agonists via P2Y12. Rac activation by P2Y1 drives PAK activation and actin polymerization.\",\n      \"method\": \"Rac-GTP pulldown assay; selective P2Y1 and P2Y12 antagonists; P2Y1 knockout mice platelets; GPIIb/IIIa and PI3K inhibitors; PAK kinase assay; actin polymerization\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mice plus selective pharmacology plus biochemical effector assays\",\n      \"pmids\": [\"16194206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"P2Y1 receptor mediates ADP-induced platelet shape changes including centralization of secretory granules, formation of filopodia, actin polymerization, and cytoskeletal translocation of cdc42, rac1, and rhoA in an integrin αIIbβ3-dependent manner. P2YT (P2Y12) receptor is required for stable macroaggregate formation and amplification of actin polymerization but not early platelet activation steps.\",\n      \"method\": \"Selective antagonists A2P5P (P2Y1) and AR-C67085 (P2Y12); electron microscopy; actin polymerization assay; subcellular fractionation for small GTPases\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective pharmacological dissection in native platelets with multiple morphological and biochemical readouts, single lab\",\n      \"pmids\": [\"11341507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"P2Y1 receptor-mediated Ca2+ signaling in astrocytes exhibits frequency-dependent negative feedback via protein kinase C, with high-frequency stimulation producing rapid Ca2+ oscillations. The PKC-dependent oscillation mechanism was mapped to Thr339 in the C-terminus of P2Y1R; mutation of this residue eliminated PKC-mediated negative feedback.\",\n      \"method\": \"Calcium imaging; PKC inhibitors; site-directed mutagenesis of P2Y1R C-terminal Thr339; frequency-dependent stimulation protocols in primary astrocytes\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis mapping to specific residue combined with calcium imaging, single lab\",\n      \"pmids\": [\"12805284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"P2Y1 receptor in rat cortical astrocytes inhibits GABA transport (GAT-1 and GAT-3) by reducing transporter Vmax. This inhibition requires PLC activation and intracellular calcium release from stores, as it was blocked by PLC inhibitor U73122, BAPTA-AM (intracellular calcium chelation), and depletion of calcium stores with cyclopiazonic acid.\",\n      \"method\": \"P2Y1-selective agonist (2-MeSADP) and antagonist (MRS2179); GABA transport kinetics (Vmax/Km); PLC inhibitor; BAPTA-AM; calcium store depletion; primary astrocyte cultures\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective pharmacology with multiple mechanistic controls (PLC, Ca2+ chelation, store depletion) in single lab\",\n      \"pmids\": [\"24733747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"P2Y1 receptor activation in satellite glial cells (SGCs) couples to and activates TRPV4 ion channel through PKC. P2Y1-selective agonist (2-MeSADP) increased [Ca2+]i in SGCs expressing TRPV4, and responses were enhanced in TRPV4-expressing HEK293 cells; PKC inhibitors prevented P2Y1 receptor activation of TRPV4.\",\n      \"method\": \"Calcium imaging in isolated DRG neurons with attached SGCs; TRPV4 knockout mice; P2Y1-selective agonist/antagonist; PKC inhibitors; HEK293 co-expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout, co-expression system, and pharmacological inhibition, single lab\",\n      \"pmids\": [\"26475857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NTPDase1 co-localizes with P2Y1 receptor in caveolae of human placental endothelial cells, and enzymatic activity of NTPDase1 controls the local concentration of ADP/ATP available to activate P2Y1R. In NTPDase1-/- mice, P2Y1 receptor-dependent endothelial relaxation is dramatically enhanced (EC50 for ADP shifted from 14 µM to 0.35 µM) and P2Y1 receptors become more extensively desensitized.\",\n      \"method\": \"Immunohistochemistry and immuno-electron microscopy of human placenta; NTPDase1 knockout mice; vascular ring relaxation assays; in vivo blood pressure measurements\",\n      \"journal\": \"European journal of histochemistry; British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout mice with functional vascular readouts and co-localization data, two independent studies\",\n      \"pmids\": [\"15590415\", \"20067476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NTPDase1 coexpression dramatically reduces P2Y1 receptor activation potency (50-fold increase in EC50 for ADP), while NTPDase2 increases apparent ATP potency at P2Y1R by converting ATP to ADP. Basal P2Y1 receptor activity is maintained by paracrine/autocrine nucleotide release and is abolished by NTPDase1.\",\n      \"method\": \"Co-expression of NTPDase1 or NTPDase2 with P2Y1R in same cell or co-culture; phospholipase C activity assays; comparison of agonist EC50 values\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic co-expression experiment with quantitative EC50 measurements, single lab\",\n      \"pmids\": [\"15496502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RhoA signaling downstream of platelet P2Y1 receptor (not P2Y12 or P2X1) mediates platelet-dependent leukocyte recruitment in allergic inflammation. P2Y1 receptor stimulation activated RhoA in vivo after allergen challenge, and ROCK1 inhibition in platelets phenocopied P2Y1 antagonism in preventing platelet-dependent leukocyte chemotaxis.\",\n      \"method\": \"Selective P2Y1 antagonist in ovalbumin-sensitized BALB/c mice; thrombocytopenia reinfusion experiments with P2Y1-antagonist or ROCK1-inhibitor pretreated platelets; RhoA activity assays; bronchoalveolar lavage cell counts\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — platelet reinfusion experiments establishing platelet-intrinsic P2Y1-RhoA pathway, selective pharmacology with multiple controls\",\n      \"pmids\": [\"25445826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ADP stimulates human endothelial cell migration via P2Y1 receptor-mediated activation of ERK1/2, JNK, and p38 MAPK pathways. Blockade of ERK or JNK (but partial inhibition with p38 blockade) abolished ADP/2-MeSADP-stimulated HUVEC migration. This was blocked by MRS2179 (P2Y1 antagonist) but not AR-C69931MX (P2Y12/13 antagonist).\",\n      \"method\": \"Boyden chamber and wound-repair migration assays; RT-PCR for receptor expression; phospho-specific Western blots; selective MAPK inhibitors (U0126, SP600125, SB203580); selective P2Y1 antagonist\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional migration assay with pathway dissection using multiple selective inhibitors, single lab\",\n      \"pmids\": [\"18174464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"P2Y1 receptor in epithelial cells transactivates EGFR to broadcast mitogenic signals via PKC, Src, and cell surface metalloproteases. P2Y1R stimulation for 15–60 min triggered proliferation; apyrase degradation of extracellular nucleotides or P2Y1R drug inhibition reduced basal cell proliferation. MDCK cells ectopically expressing P2Y1R showed a highly proliferative EGFR-dependent phenotype with increased EGFR levels.\",\n      \"method\": \"Apyrase treatment; P2Y1R pharmacological inhibition; ectopic P2Y1R expression in MDCK cells; PKC/Src/metalloprotease inhibitors; cell proliferation assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ectopic expression with pharmacological pathway dissection, single lab with multiple inhibitors\",\n      \"pmids\": [\"18057028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"P2Y1 receptor signaling in pancreatic beta cells contributes to glucose-induced pulsatile insulin secretion through autocrine activation following ATP exocytosis, generating plasma membrane DAG spikes in spatially confined microdomains. Each DAG spike causes local PKC activation and MARCKS dissociation from the plasma membrane. Inhibition of P2Y1 suppressed glucose-induced pulsatile insulin secretion.\",\n      \"method\": \"TIRF microscopy with DAG/PKC translocation biosensors; insulin secretion assay; P2Y1/P2X receptor inhibitors; exocytosis inhibition; MIN6 cells, primary mouse, and human beta cells\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live imaging biosensors with pharmacological dissection in three cell types, single lab\",\n      \"pmids\": [\"23299857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Polyphosphate amplifies proinflammatory responses of histone H4 and HMGB1 specifically through RAGE and P2Y1 receptor interaction in human umbilical vein endothelial cells, eliciting intracellular Ca2+ release. siRNA knockdown of P2Y1 and extracellular domain competitive inhibition demonstrated P2Y1 is required for polyP-mediated H4/HMGB1 inflammatory signaling.\",\n      \"method\": \"siRNA knockdown of TLR2, TLR4, RAGE, P2Y1; competitive inhibition with extracellular receptor domains; calcium release assays; in vivo inflammatory models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA plus competitive inhibition identifying specific receptor, multiple controls, single lab\",\n      \"pmids\": [\"24255918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"P2Y12 receptor (not P2Y1) is involved in thrombin-induced phosphatidylserine (PS) exposure on platelets and subsequent TF-induced thrombin generation in platelet-rich plasma. Both P2Y1 and P2Y12 contribute to platelet-leukocyte interactions and leukocyte TF exposure via P-selectin.\",\n      \"method\": \"Selective P2 antagonists MRS2179 (P2Y1) and AR-C69931MX (P2Y12); PS exposure assay; thrombin generation in platelet-rich plasma; platelet-leukocyte complex formation\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective pharmacological dissection in native human platelets, single lab with defined endpoints\",\n      \"pmids\": [\"12933533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"P2Y1 receptor mediates ADP-induced p38 MAP kinase-activating factor generation in human platelets. The P2Y1-selective antagonist A2P5P inhibited ADP-induced p38 kinase activation in a concentration-dependent manner, while the P2TAC (P2Y12) antagonist AR-C66096 did not, and P2X1-selective agonist alphabeta-meATP failed to activate p38.\",\n      \"method\": \"Selective P2Y1 antagonist (A2P5P) and P2Y12 antagonist (AR-C66096); p38 MAP kinase phosphorylation assay; aspirin-treated vs normal platelets; TX synthase inhibitor controls\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with selective antagonists in native platelets, single lab\",\n      \"pmids\": [\"10759852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"P2Y1 receptor is required for normal thermal sensitivity in cutaneous polymodal nociceptors (CPMs). P2Y1-/- mice showed significantly increased heat thresholds and decreased peak firing rates during thermal ramp stimulation, and altered cold thresholds, with no significant change in mechanical sensitivity. Most ADP-responsive DRG neurons co-express IB4 binding and P2X3.\",\n      \"method\": \"P2Y1 knockout mice; ex vivo skin-nerve-DRG-spinal cord recording preparation; ratiometric calcium imaging of isolated DRG neurons; digital thermal and mechanical stimuli\",\n      \"journal\": \"Molecular pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with direct electrophysiological recording from identified cell types and specific thermal/mechanical stimulus protocols\",\n      \"pmids\": [\"21310055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Inflammation-induced upregulation of P2Y1 receptor in DRG neurons is required for CFA-induced heat sensitization of cutaneous CPM fibers. siRNA knockdown of the P2Y1 increase during inflammation completely blocked the normal reduction of heat thresholds. P2Y1 knockdown also increased TRPV1-expressing CPM neurons without changing total TRPV1+ cells, indicating P2Y1 maintains phenotype in cutaneous TRPV1-negative afferents.\",\n      \"method\": \"In vivo siRNA knockdown targeting DRG P2Y1; CFA-induced inflammation; ex vivo electrophysiological recording; immunohistochemistry for TRPV1 expression\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo siRNA with electrophysiological and phenotypic readouts, single lab\",\n      \"pmids\": [\"22137295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Reduced P2Y1 receptor expression in Cx43-null neural progenitor neurospheres impairs calcium signaling in response to P2Y (but not P2X) agonists, and reduces proliferation and migration of neural progenitors. Ectopic expression of P2Y1R in Cx43-null cells restored migration to wild-type levels.\",\n      \"method\": \"Connexin43 knockout mice-derived neurospheres; pharmacological blockade with MRS-2179 and suramin; P2Y1R rescue by ectopic expression; calcium imaging; BrdU proliferation assay; migration assay\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — rescue by ectopic expression combined with genetic knockout and pharmacological blockade, single lab\",\n      \"pmids\": [\"14673009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BPTU (allosteric P2Y1R antagonist binding outside the helical bundle) antagonizes P2Y1R in a pattern that varies by signaling pathway and agonist used: surmountable (parallel rightward shift, unaffected Emax) for ERK1/2 and label-free readouts with 5'-diphosphate agonists, but insurmountable (suppressed Emax) for GTPgammaS binding and beta-arrestin2 recruitment, and insurmountable in all pathways with dinucleotide Ap4A. Orthosteric MRS2500 behaves as surmountable antagonist across all pathways and agonists.\",\n      \"method\": \"Multiple signaling assays (ERK1/2, GTPgammaS binding, beta-arrestin2 recruitment, label-free dynamic mass redistribution); concentration-response curve analysis with diverse agonists\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling pathway readouts with two antagonists and three agonists, single lab\",\n      \"pmids\": [\"28864555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mechanical stress in human periodontal ligament cells induces ATP release, which activates P2Y1 receptor to stimulate Rho kinase activation and subsequent osteopontin (OPN) expression upregulation. Selective P2Y1 antagonist MRS2179 and apyrase abolished stress-induced OPN expression.\",\n      \"method\": \"Mechanical stress stimulation; P2Y1 antagonist (MRS2179); apyrase; Rho kinase inhibitor; RT-PCR and Western blot for OPN\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective antagonist and enzymatic nucleotide degradation controls, single lab\",\n      \"pmids\": [\"18502966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Extracellular ATP stimulates RANKL expression in human periodontal ligament cells through P2Y1 receptor via a COX-dependent pathway involving cAMP-dependent PKA, NF-κB activation, and prostaglandin E2 production. P2Y1 siRNA and the selective antagonist MRS2179 both diminished this effect.\",\n      \"method\": \"P2Y1 siRNA; selective antagonist MRS2179; COX inhibitor indomethacin; PKA inhibitor H89; NF-κB inhibitor; PGE2 ELISA; RANKL RT-PCR and Western blot\",\n      \"journal\": \"Journal of periodontal research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA plus pharmacological inhibition of multiple pathway components, single lab\",\n      \"pmids\": [\"20337886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A1 adenosine receptor and P2Y1 receptor co-localize at synaptic membranes and surrounding astroglial membranes of glutamatergic synapses in rat hippocampus. Functionally, P2Y1 receptor stimulation impairs A1 receptor coupling to G protein, while A1 receptor stimulation increases P2Y1 receptor functional responsiveness.\",\n      \"method\": \"Postembedding immunogold electron microscopy; G protein coupling assays after receptor co-stimulation in hippocampal tissue\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — immunogold EM co-localization with functional G-protein coupling assays, single lab\",\n      \"pmids\": [\"17672857\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"P2Y1R is a Gq-coupled GPCR activated by extracellular ADP (and related dinucleotides) with two structurally characterized ligand-binding sites—an orthosteric transmembrane site and an allosteric site on the receptor–lipid bilayer interface; upon ADP binding it breaks an ionic lock and opens a water channel to activate Gq, stimulating PLC-IP3-Ca2+ mobilization, PKC, ERK1/2, JNK, and Rac/RhoA pathways; its activity is terminated by PKC-dependent desensitization, ALIX/YPX3L-mediated ubiquitin-independent lysosomal sorting, and SNX1-regulated slow recycling; it forms constitutive and agonist-induced homodimers (requiring the C-terminal DTSL motif and NHERF-2 scaffold) and hetero-oligomers with P2Y11 that redirect P2Y11 internalization and ligand selectivity; in platelets P2Y1R is essential for ADP-induced shape change, aggregation, Rac activation, and Ca2+ mobilization (with P2Y12 providing the complementary adenylyl cyclase-inhibitory limb); in astrocytes it triggers glutamate exocytosis, inhibits GABA transport, and mediates Ca2+ wave propagation; in the enteric nervous system it transduces purinergic inhibitory neurotransmission controlling colonic motility; and in sensory neurons it regulates thermal nociception and undergoes inflammation-induced upregulation that drives heat sensitization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"P2RY1 (P2Y1R) is a Gq-coupled G-protein-coupled receptor for extracellular ADP that converts purinergic signals into PLC-IP3-Ca2+ mobilization and broad downstream kinase activation across platelets, vasculature, and the nervous system [#2, #6, #13]. Reconstitution of purified receptor with heterotrimeric Gq confirms direct agonist-stimulated GTP hydrolysis with the rank order 2MeSADP > ADP >> ATP, establishing ADP as the physiological full agonist and ATP as a low-potency partial agonist/competitive antagonist [#3, #6]. Crystallography resolved two distinct ligand pockets\\u2014an orthosteric site within the transmembrane bundle occupied by nucleotide antagonists and an allosteric pocket on the receptor\\u2013lipid interface bound by BPTU\\u2014and these sites translate into distinct, pathway-dependent antagonist pharmacology [#0, #36]. Downstream of Gq, P2Y1R drives ERK1/2, JNK, and p38 signaling to Elk-1-dependent transcription, Rac/RhoA-dependent cytoskeletal remodeling, and EGFR transactivation [#13, #14, #19, #28]. Receptor activity is shaped at multiple levels: ectonucleotidases (NTPDase1/2) set local agonist availability and desensitization state [#24, #25], PKC mediates desensitization and frequency-dependent negative feedback via C-terminal Thr339 [#7, #21], and trafficking is governed by ALIX/YPX3L-directed ubiquitin-independent lysosomal sorting and SNX1-regulated slow recycling [#9, #10]. The receptor constitutively homodimerizes through a C-terminal DTSL/NHERF-2 interaction required for internalization, and hetero-oligomerizes with P2Y11 to redirect its trafficking and ligand selectivity [#8, #11]. Physiologically, P2Y1R is essential and non-redundant for ADP-induced platelet shape change, aggregation, Ca2+ mobilization, and Rac/RhoA activation, while a separate receptor (P2Y12) couples ADP to adenylyl cyclase inhibition [#4, #19, #20]; it mediates fast inhibitory purinergic neurotransmission controlling colonic motility [#16, #17], astrocytic glutamate exocytosis and GABA-transporter regulation [#15, #22], and thermal nociception, undergoing inflammation-induced upregulation that drives heat sensitization [#33, #34].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established the molecular identity of the platelet ADP receptor by showing the cloned P2Y1 receptor is an ADP-activated, calcium-mobilizing GPCR, resolving which gene transduces ADP-evoked Ca2+ signals.\",\n      \"evidence\": \"Heterologous expression in Jurkat cells with HPLC-purified nucleotide pharmacology and platelet RT-PCR\",\n      \"pmids\": [\"9038354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which receptor couples ADP to adenylyl cyclase inhibition\", \"Coupling partner (Gq) inferred pharmacologically, not biochemically\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Clarified the true agonist/antagonist profile by removing nucleotide contamination, demonstrating ADP is the full agonist and ATP a competitive antagonist, and that selective antagonists block platelet aggregation/Ca2+ but not adenylyl cyclase inhibition\\u2014splitting the platelet ADP response into two receptors.\",\n      \"evidence\": \"Purity-controlled pharmacology in endothelial and Jurkat cells, plus selective antagonists in human platelets with fura-2 imaging\",\n      \"pmids\": [\"9547364\", \"9639511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the second adenylyl-cyclase-coupled ADP receptor not yet established\", \"Antagonist binding residues not mapped\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Localized the antagonist/nucleotide binding determinants to specific transmembrane residues, providing the first structural model of where ligands engage the receptor.\",\n      \"evidence\": \"Site-directed mutagenesis with PLC functional readout and rhodopsin-based molecular modeling\",\n      \"pmids\": [\"9554879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Model based on rhodopsin homology, not direct structure\", \"Agonist binding mode not resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the downstream kinase architecture, showing P2Y1R activates ERK1/2 and JNK (but not p38) through PI3K/Src/PKC-Ras inputs converging on Elk-1, with a JNK limb driving apoptosis.\",\n      \"evidence\": \"Dominant-negative Ras/MKK4, kinase inhibitors, pertussis toxin, and caspase-3 assays in stable cell lines\",\n      \"pmids\": [\"11278310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type generality of the apoptotic JNK limb unclear\", \"Direct effector linkages inferred pharmacologically\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Proved direct Gq coupling biochemically by reconstituting purified receptor with heterotrimeric Gq, fixing the agonist rank order under conditions that prevent nucleotide metabolism.\",\n      \"evidence\": \"Receptor purification from Sf9, proteoliposome reconstitution, radioligand binding, and steady-state GTPase assays\",\n      \"pmids\": [\"14742685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other G-protein couplings not tested in this system\", \"Lipid/allosteric modulation not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed an intrinsic voltage sensitivity of P2Y1R that potentiates IP3-dependent Ca2+ release independent of voltage-gated channels, expanding the receptor's signaling repertoire.\",\n      \"evidence\": \"Patch clamp with fura-2 in megakaryocytes from P2Y1-knockout mice, with GTPgammaS/AlF4- dialysis controls\",\n      \"pmids\": [\"15528188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of voltage sensing not identified\", \"Physiological relevance outside megakaryocytes unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Distinguished P2Y1 desensitization mechanism from P2Y12, showing it is PKC-dependent rather than GRK-mediated.\",\n      \"evidence\": \"Dominant-negative GRK, GRK siRNA, and PKC inhibition in platelets and 1321N1 cells\",\n      \"pmids\": [\"15665114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PKC phosphorylation site(s) not yet mapped here\", \"Arrestin involvement not directly assessed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Assigned the Rac-activating limb of platelet ADP signaling to P2Y1R via Gq, linking the receptor to PAK and actin polymerization independently of P2Y12 and PI3K.\",\n      \"evidence\": \"Rac-GTP pulldowns, selective antagonists, P2Y1-knockout platelets, and PAK/actin assays\",\n      \"pmids\": [\"16194206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the GEF coupling Gq to Rac not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapped the determinants of receptor oligomerization and trafficking, showing constitutive/agonist-induced homodimerization via the C-terminal DTSL motif and NHERF-2 is required for internalization but not activation, and that P2Y1 hetero-oligomerizes with P2Y11 to control its endocytosis and ligand selectivity.\",\n      \"evidence\": \"Live-cell FRET, C-terminal deletion mutants, co-IP/co-pulldown, and siRNA rescue in HEK293/1321N1 cells\",\n      \"pmids\": [\"18270199\", \"17824841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of higher-order oligomers unresolved\", \"In vivo relevance of P2Y1-P2Y11 heteromers not shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined the post-activation degradative fate of P2Y1R as a ubiquitin-independent ALIX/YPX3L-dependent lysosomal sorting pathway, complementing an earlier SNX1-regulated slow recycling route.\",\n      \"evidence\": \"ALIX siRNA, YPX3L motif mutagenesis, and degradation/recycling microscopy; SNX1 and retromer manipulation\",\n      \"pmids\": [\"27301021\", \"20070609\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Switch between recycling and degradation fates not defined\", \"Single-lab findings for each trafficking route\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided atomic-resolution structures revealing two spatially distinct ligand pockets\\u2014orthosteric (intra-helical) and allosteric (lipid-interface)\\u2014establishing a structural basis for the receptor's dual antagonist pharmacology.\",\n      \"evidence\": \"X-ray crystallography of MRS2500 and BPTU complexes, with all-atom MD simulations of the activation mechanism\",\n      \"pmids\": [\"25822790\", \"27460867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No active-state agonist-bound or Gq-coupled structure\", \"MD activation model lacks mutagenesis validation\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that allosteric vs orthosteric antagonism produces pathway- and agonist-biased blockade, refining how the two binding sites translate into functional pharmacology.\",\n      \"evidence\": \"ERK1/2, GTPgammaS, beta-arrestin2, and label-free assays with multiple agonists and antagonists\",\n      \"pmids\": [\"28864555\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of probe dependence not resolved\", \"Single-lab dataset\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified physiological purinergic neurotransmitters and gut function for P2Y1R, showing it mediates fast inhibitory junction potentials and Up4A-evoked relaxation controlling colonic motility.\",\n      \"evidence\": \"P2ry1-knockout mice with intracellular electrophysiology, contractility, transit imaging, and heterologous Ca2+ assays\",\n      \"pmids\": [\"22371476\", \"25341729\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source and regulation of endogenous beta-NAD/Up4A release not fully defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established astrocytic and glial roles for P2Y1R, coupling it to regulated glutamate exocytosis (via TNFalpha/PGE2), GABA-transporter inhibition, and PKC-gated Ca2+ oscillation feedback at C-terminal Thr339.\",\n      \"evidence\": \"TIRF vesicle imaging, knockout mice, PLC/Ca2+ chelation controls, and C-terminal mutagenesis in primary astrocytes\",\n      \"pmids\": [\"16882655\", \"24733747\", \"12805284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of these glial outputs in intact circuits incompletely defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a sensory role, showing P2Y1R is required for normal thermal nociceptor sensitivity and that inflammation-driven upregulation mediates heat sensitization.\",\n      \"evidence\": \"P2Y1-knockout mice and in vivo DRG siRNA with ex vivo skin-nerve recording and DRG calcium imaging\",\n      \"pmids\": [\"21310055\", \"22137295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between P2Y1 and TRPV1-channel modulation not fully resolved\", \"Inflammation upregulation mechanism not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the two structurally defined ligand sites, oligomerization state, and ectonucleotidase-set agonist microenvironment integrate to dictate biased signaling and tissue-specific output in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No active-state structure with Gq\", \"No unified model linking dimerization/heteromerization to signaling bias in native tissue\", \"Determinants of recycling-vs-degradation fate undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 6, 3]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [24, 11, 8]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [9, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 6, 13]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [4, 20, 19]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [15, 16, 33]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"P2RY11\", \"NHERF2\", \"PDCD6IP\", \"SNX1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}